4-[4-(4-Fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-3-butyn-1-ol (BioDeep_00000173686)

   

human metabolite blood metabolite


代谢物信息卡片


4-[4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-(pyridin-4-yl)-1H-imidazol-2-yl]but-3-yn-1-ol

化学式: C27H24FN3O (425.1903306)
中文名称: 4-(4-氟苯基)-2-(4-羟基-1-丁炔)-1-(3-苯基丙基)-5-(4-吡啶基)咪唑
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: C1=CC=C(C=C1)CCCN2C(=NC(=C2C3=CC=NC=C3)C4=CC=C(C=C4)F)C#CCCO
InChI: InChI=1S/C27H24FN3O/c28-24-13-11-22(12-14-24)26-27(23-15-17-29-18-16-23)31(25(30-26)10-4-5-20-32)19-6-9-21-7-2-1-3-8-21/h1-3,7-8,11-18,32H,5-6,9,19-20H2

描述信息

同义名列表

5 个代谢物同义名

4-[4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-(pyridin-4-yl)-1H-imidazol-2-yl]but-3-yn-1-ol; 4-[4-(4-Fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-3-butyn-1-ol; 4-(4-(4-Fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol-2-yl)-3-butyn-1-ol; 4-[4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-(pyridin-4-yl)imidazol-2-yl]but-3-yn-1-ol; RWJ 67657



数据库引用编号

5 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • J Westra, J Bijzet, B Doornbos-van der Meer, M H van Rijswijk, P C Limburg. Differential influence of p38 mitogen activated protein kinase (MAPK) inhibition on acute phase protein synthesis in human hepatoma cell lines. Annals of the rheumatic diseases. 2006 Jul; 65(7):929-35. doi: 10.1136/ard.2005.043232. [PMID: 16269426]
  • Daniel E Frigo, Aninda Basu, Erica N Nierth-Simpson, Christopher B Weldon, Christine M Dugan, Steven Elliott, Bridgette M Collins-Burow, Virgilio A Salvo, Yun Zhu, Lilia I Melnik, Gabriela N Lopez, Peter J Kushner, Tyler J Curiel, Brian G Rowan, John A McLachlan, Matthew E Burow. p38 mitogen-activated protein kinase stimulates estrogen-mediated transcription and proliferation through the phosphorylation and potentiation of the p160 coactivator glucocorticoid receptor-interacting protein 1. Molecular endocrinology (Baltimore, Md.). 2006 May; 20(5):971-83. doi: 10.1210/me.2004-0075. [PMID: 16410316]
  • Marjolin N Lub-de Hooge, Steven de Jong, Claudine Vermot-Desroches, Jaap E Tulleken, Elisabeth G E de Vries, Jan G Zijlstra. Endotoxin increases plasma soluble tumor necrosis factor-related apoptosis-inducing ligand level mediated by the p38 mitogen-activated protein kinase signaling pathway. Shock (Augusta, Ga.). 2004 Aug; 22(2):186-8. doi: 10.1097/01.shk.0000132486.82177.ec. [PMID: 15257094]
  • Jan G Zijlstra, Jaap E Tulleken, Jack J M Ligtenberg, Peter de Boer, Tjip S van der Werf. p38-MAPK inhibition and endotoxin induced tubular dysfunction in men. Journal of endotoxin research. 2004; 10(6):402-5. doi: 10.1179/096805104225005869. [PMID: 15588422]
  • Dolly A Parasrampuria, Peter de Boer, Daksha Desai-Krieger, Andrew T Chow, C Richard Jones. Single-dose pharmacokinetics and pharmacodynamics of RWJ 67657, a specific p38 mitogen-activated protein kinase inhibitor: a first-in-human study. Journal of clinical pharmacology. 2003 Apr; 43(4):406-13. doi: 10.1177/0091270002250615. [PMID: 12723461]
  • J W Fijen, J G Zijlstra, P De Boer, R Spanjersberg, J W Tervaert, T S Van Der Werf, J J Ligtenberg, J E Tulleken. Suppression of the clinical and cytokine response to endotoxin by RWJ-67657, a p38 mitogen-activated protein-kinase inhibitor, in healthy human volunteers. Clinical and experimental immunology. 2001 Apr; 124(1):16-20. doi: 10.1046/j.1365-2249.2001.01485.x. [PMID: 11359438]